LONGBIO-B

LongBio Pharma (Suzhou) Co., Ltd. discovers and develops biopharmaceuticals targeting allergic and autoimmune diseases in the People's Republic of China and Hong Kong. Its products include LP-003, an anti-IgE antibody with novel sequencing; LP-005, a bi-functional antibody fusion protein; LP-00A, a bi-functional antibody for allergic diseases; LP-00C, a bi-functional antibody or fusion protein for B-cell mediated autoimmune diseases; and LP-00D, a bi-functional antibody or fusion protein complement inhibitor for specific tissues, organs and indications. The company was founded in 2020 and is based in Changshu, China.